Iconoclast,

I may have missed it, but the low eGFR patients did not have improved kidney fucntion (in the data I have viewed), they had lowered MACE events.  And it was a whopping 50% RRR in MACE for a subgroup that had the twice the MACE rate as did the whole trial.  This a great result, but, at the risk of being somewhat, ahh... repetitive, the sample size of CKD patients was very small.  As a result, you have to take that 50% with a shakerful of salt, it is an estimate with a very wide confidence interval if tested properly.  Think of our expected 30% reduction in MACE that shrank to 18% when tested with a larger sample size...

Jupe